Haemonetics Corporation filed an 8-K on August 18, 2026, disclosing a supply agreement entered into on August 14, 2026, with CSL Plasma Inc. for the use of Haemonetics NexSys PCS devices with Persona PLUS technology and related disposables in the United States.

Key Highlights

  • Agreement date: Haemonetics entered the supply agreement with CSL Plasma Inc. on August 14, 2026.
  • Products covered: The agreement covers NexSys PCS devices with Persona PLUS technology and the purchase of related disposables in the United States.
  • Non-exclusive, no minimums: The supply agreement is non-exclusive and does not contain minimum purchase commitments, according to the filing.
  • Partial transition expected: Haemonetics anticipates CSL will transition a portion of its U.S. plasma collection centers to the company's devices and disposables, but the scope and timing have not yet been determined.
  • Guidance unchanged: The company stated it is not updating its previously issued fiscal 2027 guidance at this time.
  • Update timeline: The company expects to provide an update on the anticipated impact of the agreement on fiscal 2027 financial results during its second fiscal quarter earnings call in November 2026.

Haemonetics and CSL Plasma Supply Agreement: Key Terms and Outlook

Haemonetics Corporation (NYSE:HAE) disclosed in its August 18, 2026 filing under Item 7.01 (Regulation FD Disclosure) that it entered into a supply agreement with CSL Plasma Inc. on August 14, 2026. Under the agreement, CSL may utilize the company's NexSys PCS devices with Persona PLUS technology and purchase related disposables for use in the United States. The filing specifies that the agreement is non-exclusive and contains no minimum purchase commitments.

According to the filing, Haemonetics anticipates that CSL will transition a portion of its U.S. plasma collection centers to the company's devices and disposables. However, the company noted that "the scope and timing of implementation have not yet been determined." As a result, Haemonetics stated it is not revising its previously issued fiscal 2027 financial guidance at this time.

The company indicated it expects to address the anticipated financial impact of the agreement during its second fiscal quarter earnings call, scheduled for November 2026. The filing also notes that the information disclosed under Item 7.01 "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934." The filing includes forward-looking statements, which the company described as subject to risks and uncertainties including customer demand, the timing and volume of CSL purchases, and the company's ability to manufacture and supply its products.

What Was Disclosed

Haemonetics disclosed a non-exclusive supply agreement with CSL Plasma Inc., dated August 14, 2026, covering NexSys PCS devices with Persona PLUS technology and disposables in the U.S. No minimum purchase commitments are included, and fiscal 2027 guidance was not updated.